Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s share price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$1.77 and traded as low as C$1.57. Helix BioPharma shares last traded at C$1.57, with a volume of 643 shares changing hands.
Helix BioPharma Trading Down 0.6%
The business has a fifty day simple moving average of C$1.77 and a 200 day simple moving average of C$1.99. The company has a market cap of C$119.91 million, a price-to-earnings ratio of -26.17 and a beta of 0.40. The company has a quick ratio of 1.04, a current ratio of 0.04 and a debt-to-equity ratio of 2.34.
Helix BioPharma (TSE:HBP – Get Free Report) last announced its quarterly earnings results on Monday, March 16th. The biopharmaceutical company reported C($0.01) EPS for the quarter. On average, equities analysts anticipate that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.
About Helix BioPharma
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Further Reading
- Five stocks we like better than Helix BioPharma
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
